Search results
Hyderabad GCCs Lease 31% of Office Space in H1 2024 | Hyderabad News - Times of India
The Times of India· 2 days agoHyderabad: Global capability centres (GCCs), which have emerged as key drivers of office space absorption in the country, accounted for 60% or 3 million sq ft of the total 5 msft office space ...
Pentixapham acquires antibody discovery business of Glycotope
Pharmaceutical Technology· 3 days agoLilly has signed two high-profile deals for radiopharmaceuticals; a $140m partnership with...
LOTTE BIOLOGICS breaks ground on biopharma plant in Incheon
Pharmaceutical Technology· 3 days agoFounded in 2022, LOTTE BIOLOGICS entered the contract development and manufacturing organisation...
5 FDA decisions to watch in the third quarter
BioPharma Dive· 4 days agoMultibillion-dollar buyouts from Bristol Myers Squibb and Gilead could yield new drugs for brain and liver diseases, while a new cell therapy may reach...
Eli Lilly continues radiopharma push with $140m Radionetics partnership
Pharmaceutical Technology· 5 days agoBristol Myers Squibb (BMS) also made a big sign of its intent in this arena when it dropped $4.2bn...
Eisai and Bristol Myers Squibb terminate ADC development deal
Pharmaceutical Technology· 5 days agoEisai has announced the termination of its worldwide strategic collaboration with Bristol Myers ...
CAR-T landscape set to expand in 2024
Clinical Trials Arena· 5 days agoKey major players in this field are Novartis, Gilead, and Bristol Myers Squibb. Bristol Myers Squibb is one of the ...
Vivos eyes human trials for radiation treatment gel with IDE submission
Clinical Trials Arena· 6 days agoBig pharma has made plays for the space in the past year too, with Eli Lilly, Novartis and Bristol...
Bristol Myers to pay $2.7 mln to settle Israel anti-competition charges - ET HealthWorld | Pharma
The Economic Times· 6 days agoJerusalem: Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to...
Eisai and Bristol Myers cancel cancer ADC deal
BioPharma Dive· 6 days agoThe Japan-based drugmaker said its U.S. partner’s “portfolio prioritization efforts” led to the termination. It will refund part of an upfront payment.
